Hui-Chun Hsu1,2, Su-Yu Tsai1, Shang-Liang Wu3, Shiow-Roug Jeang1, Mei-Yao Ho2, Wen-Shiung Liou4,5,6, An-Jen Chiang7,8,9,10, Tsung-Hsien Chang11. 1. Department of Nursing, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. 2. Health Care and the University of Technology Graduate School of The Meiho University, Pingtung, Taiwan. 3. Environment and Population Health, Griffith University, Nathan, Australia. 4. Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, 386, Ta-Chung 1st Road, Kaohsiung, 813, Taiwan, Republic of China. 5. Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan. 6. Department of Obstetrics and Gynecology, National Defense Medical Center, Taipei, Taiwan. 7. Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, 386, Ta-Chung 1st Road, Kaohsiung, 813, Taiwan, Republic of China. ajchiang490111@gmail.com. 8. Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan. ajchiang490111@gmail.com. 9. Department of Obstetrics and Gynecology, National Defense Medical Center, Taipei, Taiwan. ajchiang490111@gmail.com. 10. Department of Obstetrics and Gynecology, National Yang-Ming University, Taipei, Taiwan. ajchiang490111@gmail.com. 11. Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Abstract
PURPOSE: This study aimed to assess the incidence and difference of side effects among six courses of chemotherapy (C/T) in gynecological cancer patients. METHODS: The study period was from Sep. 2010 to Dec. 2011 at the Kaohsiung Veterans General Hospital in Taiwan. The treating protocols, courses, and drugs of C/T in patient were considered according to the different malignant cancers and clinical conditions. The patient data of age, marriage status, education, religion, and experiences of C/T were collected. The patients' or their families' reported side effects of C/T were recorded daily from the beginning of C/T to the 10th day after C/T in each cycle and every course of C/T. RESULTS: Total 89 patients enrolled into the study received total 450 courses of C/T. The mean age was 54.52 ± 11.02. Ovarian cancer was the most common malignant disease (64.0%). The most often combination of drugs used was Taxol and carboplatin (40.9%). Patients complained peripheral numbness of limbs, with the highest incidence of 58.6%. The side effects with incidence about 50% were decreased fatigue (55.0%) and hair loss (49.9%). Other side effects with different levels of incidence were also noticed, such as lack of appetite, changes in taste, and muscle ache. The incidences of peripheral limb numbness and hair loss were increased with following courses of C/T. The high incidence of fatigue did not show variation between different courses of C/T. CONCLUSION: This study revealed the incidence of side effects and occurrence timing during C/T in patients with gynecological cancer. These data provide substantial information to patients and their families to understand the potential side effects of C/T courses, which might increase their compliance in receiving adjuvant C/T. Relieving the side effects in C/T would be important to improve their quality of daily life and treatment willingness.
PURPOSE: This study aimed to assess the incidence and difference of side effects among six courses of chemotherapy (C/T) in gynecological cancerpatients. METHODS: The study period was from Sep. 2010 to Dec. 2011 at the Kaohsiung Veterans General Hospital in Taiwan. The treating protocols, courses, and drugs of C/T in patient were considered according to the different malignant cancers and clinical conditions. The patient data of age, marriage status, education, religion, and experiences of C/T were collected. The patients' or their families' reported side effects of C/T were recorded daily from the beginning of C/T to the 10th day after C/T in each cycle and every course of C/T. RESULTS: Total 89 patients enrolled into the study received total 450 courses of C/T. The mean age was 54.52 ± 11.02. Ovarian cancer was the most common malignant disease (64.0%). The most often combination of drugs used was Taxol and carboplatin (40.9%). Patients complained peripheral numbness of limbs, with the highest incidence of 58.6%. The side effects with incidence about 50% were decreased fatigue (55.0%) and hair loss (49.9%). Other side effects with different levels of incidence were also noticed, such as lack of appetite, changes in taste, and muscle ache. The incidences of peripheral limb numbness and hair loss were increased with following courses of C/T. The high incidence of fatigue did not show variation between different courses of C/T. CONCLUSION: This study revealed the incidence of side effects and occurrence timing during C/T in patients with gynecological cancer. These data provide substantial information to patients and their families to understand the potential side effects of C/T courses, which might increase their compliance in receiving adjuvant C/T. Relieving the side effects in C/T would be important to improve their quality of daily life and treatment willingness.
Entities:
Keywords:
CIPN; Chemotherapy; Gynecological cancer; Peripheral neuropathy; Side effects
Authors: R J Gralla; D Osoba; M G Kris; P Kirkbride; P J Hesketh; L W Chinnery; R Clark-Snow; D P Gill; S Groshen; S Grunberg; J M Koeller; G R Morrow; E A Perez; J H Silber; D G Pfister Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: V Mock; A Atkinson; A Barsevick; D Cella; B Cimprich; C Cleeland; J Donnelly; M A Eisenberger; C Escalante; P Hinds; P B Jacobsen; P Kaldor; S J Knight; A Peterman; B F Piper; H Rugo; P Sabbatini; C Stahl Journal: Oncology (Williston Park) Date: 2000-11 Impact factor: 2.990
Authors: J L Pater; W S Lofters; B Zee; E Dempsey; D Walde; J P Moquin; K Wilson; P Hoskins; R M Guevin; S Verma; R Navari; J E Krook; J Hainsworth; M Palmer; C Chin Journal: Ann Oncol Date: 1997-02 Impact factor: 32.976
Authors: Mark G Kris; Paul J Hesketh; Mark R Somerfield; Petra Feyer; Rebecca Clark-Snow; James M Koeller; Gary R Morrow; Lawrence W Chinnery; Maurice J Chesney; Richard J Gralla; Steven M Grunberg Journal: J Clin Oncol Date: 2006-05-22 Impact factor: 44.544
Authors: H J Schmoll; M S Aapro; S Poli-Bigelli; H-K Kim; K Park; K Jordan; J von Pawel; H Giezek; T Ahmed; C Y Chan Journal: Ann Oncol Date: 2006-03-08 Impact factor: 32.976
Authors: Belinda Rina Marie Spagnoletti; Linda Rae Bennett; Christina Keenan; Suman Surendra Shetty; Lenore Manderson; Barbara McPake; Siswanto Agus Wilopo Journal: Reprod Health Date: 2022-03-19 Impact factor: 3.223
Authors: Ingeborg Klymiuk; Ceren Bilgilier; Alexander Mahnert; Andreas Prokesch; Christoph Heininger; Ingeborg Brandl; Hanka Sahbegovic; Christian Singer; Thorsten Fuereder; Christoph Steininger Journal: Front Oncol Date: 2022-08-09 Impact factor: 5.738
Authors: Guglielmo Stabile; Lara Sancin; Pierino Boschian Bailo; Chiara Ripepi; Andrea Romano; Stefania Carlucci; Giuseppe Ricci Journal: Int J Environ Res Public Health Date: 2022-09-18 Impact factor: 4.614